Drugs / TransCon IL-2 β/γ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05980598 | Sep 2023 → Mar 2025 | head and neck squamous cell carcinoma | Ascendis Pharma A/S | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransCon IL-2 β/γ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05980598 ↗ |
| Known as | TC IL-2 β/γ | “TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma” NCT05980598 ↗ |
| Route | Intravenous | “TransCon IL-2 β/γ as a 30-minute IV infusion” NCT05980598 ↗ |